Forest Delays Savella Launch: FDA Reviewing Tablet Color Change
This article was originally published in The Pink Sheet Daily
Executive Summary
Delay not expected to impact long-term sales, analysts predict.
You may also be interested in...
Forest Acquires U.S. Rights To Nycomed's Oral COPD Drug Daxas
After long development haul, PDE-4 inhibitor finally gets adopted by a commercial parent, ahead of approval.
Forest Acquires U.S. Rights To Nycomed's Oral COPD Drug Daxas
After long development haul, PDE-4 inhibitor finally gets adopted by a commercial parent, ahead of approval.
Offsetting The Pain: Forest Pushes Savella To Dampen A Lexapro Sales Slide
Forest's Savella is gaining 1,200 to 1,300 new prescribers per week and now has a 3.5 percent share of the market for fibromyalgia treatments